Genfit (NASDAQ:GNFT) Shares Down 2% - Time to Sell?

Shares of Genfit S.A. (NASDAQ:GNFT - Get Free Report) fell 2% during mid-day trading on Friday . The stock traded as low as $3.45 and last traded at $3.47. 7,808 shares were traded during trading, a decline of 7% from the average session volume of 8,393 shares. The stock had previously closed at $3.54.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Genfit in a report on Friday, February 7th.

Genfit Trading Up 2.1 %

The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. The firm has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $4.40.

Hedge Funds Weigh In On Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC bought a new position in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of Genfit as of its most recent SEC filing. 2.24% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.